RARA CRAFT DATABASE for FDA Medical Devices
510(k)K251152

FDA DEVICE FACTS

DBLG2

Diabeloop

Verified FDA Record identity for medical-device development research. This overview uses only fields stated in the FDA Record and is not a Device Description.医療機器開発の調査用に、確認済みの FDA Record の識別情報を示しています。この概要は FDA Record に記載された項目だけによるもので、機器説明ではありません。

PCCP: Authorized
DECISION DATEDecember 19, 2025PRODUCT CODEQJICLINICAL AREAClinical Laboratory

Indications for use

DBLG2, a mobile application with algorithm technology, is intended for use with compatible integrated continuous glucose monitors (iCGM) and alternate controller enabled (ACE) insulin infusion pumps to automatically increase, decrease, and suspend delivery of basal insulin based on iCGM readings and predicted glucose values. It can also deliver correction boluses when glucose values are predicted to exceed a predefined threshold. To do this, the DBLG2 software takes into account the patient's profile, glycemia (current and predicted), announced meals and physical activities. - DBLG2 is intended for the management of type 1 diabetes mellitus in persons 12 years of age and greater. - DBLG2 is intended for single patient use. - DBLG2 is Rx - For Prescription Use Only.

Form name : N/A
Revision : N/A

Tables marked from the FDA document were reconstructed automatically. Check the original FDA document (links at the end of this page) for authoritative values.

See the full product information製品情報をすべて見るには

Device description, AI/software, PCCP, evaluation and limitations are available with an account: seven days of full access after free registration, then with the paid plan.機器の説明、AI・ソフトウェア、PCCP、評価、制限事項は、アカウントでご覧いただけます。無料登録から 7 日間はすべて利用でき、その後は有料プランでご利用いただけます。

Start free 7-day access7日間無料で利用するLog inログイン

OFFICIAL FDA SOURCES

FDA Record and Public Document Status

Record and document link states are stored separately.FDA Record と公開文書のリンクの状態は、別々に記録しています。

Information reviewed:情報の確認日: July 28, 2026